Forgot Password?
Return to Course Listing

CME: Hypoparathyroidism: Optimizing pharmacotherapeutic management strategies

Activity Description / Statement of Need:

In this online, self-learning activity:

Hypoparathyroidism is a rare disorder characterized by decreased function of parathyroid glands resulting in low levels of parathyroid hormone (PTH). There are a variety of causes, including autoimmune disease, congenital defects, unintended parathyroid removal during thyroidectomy, or damage caused by radiation therapy. In a normal functioning parathyroid gland, PTH is secreted in response to low serum-ionized calcium. According to one study, nearly 60,000 people in the United States have been diagnosed with the disorder, with about 73% caused by surgery. Another study estimated the prevalence of primary hypoparathyroidism at 40 per 100,000 people in the United States.

Target Audience:

The following healthcare professionals: endocrinologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in endocrinology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with hypoparathyroidism.


Commercial Support Disclosure: This program is supported by educational grants from Takeda / Shire.

This activity is free of charge.


Release Date: June 22, 2020 -- Expiration Date: June 22, 2022

Faculty: Braden Barnett , MD

Agenda

Introduction, Disclosures

The epidemiology and clinical features of hypoparathyroidism

  • Understanding the prevalence and recognizing the most common causes of hypoparathyroidism in the US.
  • Clinical presentation and diagnosis
  • The pathophysiologic relationship between hypoparathyroidism and its complications

Treatment of hypoparathyroidism

  • Goals of therapy
  • Management of mineral homeostasis caused by the disorder
  • Therapeutic interventions available
  • Emerging therapies
  • Adverse effects of available treatment options
  • Patient case(s)

Barriers to optimal care

  • Limited knowledge of the disorder
  • Limited treatment options available
  • Effects on QOL

Summary and conclusions

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the pathophysiology and manifestations of hypoparathyroidism and discuss how they may have relevance to treatment targets.
  • Define patient-specific goals, identify treatments directly treating hypoparathyroidism, and incorporate both in the development of a treatment plan in patient cases.
  • Describe goals and mainstays of supportive care in hypoparathyroidism and apply them to patient cases.
  • Describe barriers to care in the optimal treatment of hypoparathyroidism and suggest strategies for ameliorating them.

Accreditation

ACCME Activity #201861256

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Braden G. Barnett, MD, Keck School of Medicine, USC, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Commercial Support Disclosure: This program is supported by educational grants from Takeda / Shire

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Postmenopausal osteoporosis risk stratification and treatment of those at high risk for fracture

Optimizing Primary and Secondary Fracture Prevention in Men with Osteoporosis

The current and emerging landscape of pediatric growth hormone deficiency (GHD) pharmacotherapy